Pleural Drainage Strategy After IPC Placement: A Focused Clinical Review.
Publication Title
J Bronchology Interv Pulmonol
Document Type
Article
Publication Date
2-2-2021
Keywords
washington; seattle; swedish cancer
Abstract
The first indwelling pleural catheter (IPC) received Federal Drug Administration approval in 1997, nearly 40 years after John Chambers first described instillation of talc into the pleural space for palliation of malignant pleural effusions. Since then IPCs have revolutionized the management of malignant pleural effusions, providing an effective means of controlling dyspnea in the end stages of life without the pain and prolonged hospital stays long associated with chemical sclerosing agents. While palliation of symptoms is the primary purpose of IPCs, development of pleurodesis in the outpatient setting is often an important secondary goal. Historically, decisions regarding IPC drainage frequency have been largely arbitrary and only recently has the evidence started to emerge regarding the effects of specific drainage strategies on both symptom control and pleurodesis development. This focused clinical review explores the current literature regarding IPC drainage strategies as well as novel methods designed to improve the efficacy of IPCs in a thorough and systematic manner. In addition, this review provides an in-depth analysis and synthesis of the data focusing on key considerations needed to develop patient-centered and cost-effective strategies for the use of IPCs in malignancy.
Clinical Institute
Cancer
Specialty/Research Institute
Swedish Thoracic Surgery
Specialty/Research Institute
Pulmonary Medicine
Specialty/Research Institute
Oncology
